Stocks · MOREPENLAB

Morepen Laboratories delivery percentage & share price.

· data for the trading session of Wed 18 Nov 2026

Last close · 18 Nov 2026
₹92.37 +2.20%
NSE: MOREPENLAB · BSE: 500288
⚠ Under NSE surveillance: Long-term ASM Stage IV
Sector: Pharma & healthcare · RS rating 93
1W-4.5%1M-24.0%3M+4.5%6M+117.2%1Y+102.1%
52-week range
₹33.05-38.7% from the high₹150.70

Price, volume and delivery

Candles adjusted for splits and bonuses. In the lower panel, the grey bar is the day’s volume and the coloured bar is the part that was delivered; bright green marks big-buyer days (delivered shares 3× the stock’s normal or more, with a normal-or-higher delivery %).

Morepen Laboratories share price today: what happened on 18 November

Written from NSE’s end-of-day data for 18 Nov 2026. Updated every trading evening. Facts, not advice.

Morepen Laboratories rose to ₹92.37 on Wednesday, 18 November 2026, up ₹1.99 or 2.20% from the previous close of ₹90.38. It opened at ₹89.48 and traded between ₹87.66 and ₹93.80, a range of 6.8% of its price, and finished in the middle of it. Among the 126 Pharma & healthcare stocks we track, it ranked 10th by today’s move; the typical stock in the sector moved -0.53%.

It closed higher on 4 of the last 10 sessions and is -8.8% over that stretch. Looking further back: one week -4.5%, one month -24.0%, three months +4.5%, one year +102.1%. Its relative strength (RS) rating is 93 on a 1–99 scale, which means its 12-month performance beats about 93% of the 1,443 most traded NSE stocks.

21.03 lakh shares changed hands, worth about ₹19.2 crore, 0.4 times the 20-session average, a quieter day than usual. Of those, 0% (0 shares) were taken for delivery, meaning they actually changed owners instead of being traded within the day. That compares with a 60-session average of 17%, so more of today’s trading was intraday than usual. There were 2 big-buyer days (delivery several times above normal) in the last three months.

The close is 20.7% below the 50-day average of ₹116.47 and 34.4% above the 200-day average of ₹68.73. The 14-day RSI, a 0–100 gauge of recent momentum, reads 37, in the neutral zone between 30 and 70. It sits 38.7% below its 52-week high of ₹150.70 and 179.5% above the low of ₹33.05, around the middle of the year’s range.

Looking at where shares were actually delivered over the past year, the busiest price zone below today’s close is around ₹78.50 (-15.2%), and the busiest zone above it is around ₹119 (+28.7%). Prices often slow down near such zones because many holders bought there, but they are history, not predictions.

NSE has it under surveillance (Long-term ASM Stage IV), which can mean tighter trading rules.

On a typical day Morepen Laboratories moves about ±3.8%, and its average session spans 6.3% from high to low. It closed higher on 46% of the sessions in the past year. It opened with a gap of 1% or more 65 times in that year (36 up, 29 down). Its best day of the year was 4 August 2026 (+20.00%) and its worst was 15 September 2026 (-8.26%).

Last five sessions

DayCloseChangeVolumeDelivery
Wed 18 Nov₹92.37+2.20%21.03 lakh0%
Tue 17 Nov₹90.38-4.52%40.37 lakh0%
Mon 16 Nov₹94.66-5.00%41.23 lakh0%
Fri 13 Nov₹99.64+4.99%26.43 lakh0%
Thu 12 Nov₹94.90-1.90%32.89 lakh0%

Price levels by delivered volume

Where the most Morepen Laboratories shares were actually delivered over the last year. Each day’s delivered shares are spread across that day’s high–low range; the peaks are the busiest price zones. Below the close: support zones; above: resistance zones. History, not a forecast.

₹119₹92₹78₹60₹52
  • Resistance 1₹119+28.7% · 7.6% of the year’s delivery
  • Last close₹92.3718 Nov
  • Support 1₹78.50-15.2% · 5.1% of the year’s delivery
  • Support 2₹60.00-35.0% · 7.2% of the year’s delivery
  • Support 3₹51.50-44.1% · 4.5% of the year’s delivery

Morepen Laboratories score

Ranked 0–100 against 1,356 NSE stocks (prices of 18 Nov 2026). Relative ranks for learning, not advice.

Quality
50 /100
Average
#71 of 116 in Pharma & healthcare
Valuation
52 /100
Fair
#43 of 111 in Pharma & healthcare
Momentum
62 /100
Neutral
#66 of 114 in Pharma & healthcare

Passes 10 of 15 checks on the 18-point checklist.

See how Morepen Laboratories’s scores are made and the full checklist →

Morepen Laboratories at a glance

  • Morepen Laboratories closed at ₹92.37 on 18 Nov 2026 (+2.20% on the day). Over the past year it is +102.08%, against -2.39% for NIFTY 50.
  • It trades 38.7% below its 52-week high of ₹150.70 and 179.5% above its low of ₹33.05.
  • 0% of the shares traded on 18 Nov were delivered, against a 60-session average of 17%.
  • It had 2 big-buyer days (delivery 3× its normal or more) in the last three months.
  • A typical day moves it about ±3.8%: more volatile than 97% of the 1,443 most traded NSE stocks.
  • Fundamentals: P/E 26.9 · Profit +117% YoY.

Morepen Laboratories company details

From the exchanges’ own records: NSE and BSE listings and their industry classification.

Sector
Pharma & healthcare
Industry
Pharmaceuticals
Macro sector
Healthcare
ISIN
INE083A01026
NSE symbol
MOREPENLAB
BSE code
500288
Listed on NSE since
24 November 1999
Face value
₹2 per share

Morepen Laboratories pros and cons

Written automatically from the latest results, shareholding, valuation against its sector, and price and delivery data. Facts, not advice.

Pros

  • Profit up 117% on a year ago (quarter ended Sep 2026).
  • Sales up 81% on a year ago.
  • Foreign investors (FIIs) raised their stake by 2.0 points last quarter, to 3.4%.
  • P/E of 26.9 is below its sector’s median of 41.6.
  • Relative strength rating 93 out of 99: it has outperformed most stocks over the past year.

Cons

  • Negative free cash flow in the last full year (capex exceeded operating cash flow).
  • 39% below its 52-week high.
  • More volatile than 97% of the most traded NSE stocks.

Morepen Laboratories stock DNA

Where Morepen Laboratories sits among the 1,443 most traded NSE stocks, on a 0–100 scale: 0 is the lowest of all of them, 100 the highest. From the last year of daily data. The first row is the RS rating used on our relative strength ranking.

Relative strength (RS rating)12-month return, latest quarter counted twice
Weak
Strong
93/100
Volatility61% a year
Calm
Wild
97/100
Daily range6.3% high to low
Tight
Wide
97/100
Opening gaps26% of days gap 1%+
Rare
Often
76/100
Delivery17% of volume delivered
Traders
Holders
2/100
Liquidity₹121 Cr a day
Thin
Deep
89/100
1-year return+102.1%
Laggard
Leader
95/100
Gap-ups of 1%+ (1 year)3647% filled the same day
Gap-downs of 1%+2952% filled the same day
Up days46%of the last 250 sessions
Streak1 upsessions in a row

How Morepen Laboratories usually moves

Every session of the last year by size of move. The white line is the last session.

-9.0% to -8.0%: 1 days-8.0% to -7.0%: 1 days-7.0% to -6.0%: 3 days-6.0% to -5.0%: 2 days-5.0% to -4.0%: 19 days-4.0% to -3.0%: 12 days-3.0% to -2.0%: 26 days-2.0% to -1.0%: 36 days-1.0% to +0.0%: 36 days+0.0% to +1.0%: 18 days+1.0% to +2.0%: 31 days+2.0% to +3.0%: 14 days+3.0% to +4.0%: 14 days+4.0% to +5.0%: 15 days+5.0% to +6.0%: 4 days+6.0% to +7.0%: 5 days+7.0% to +8.0%: 2 days+8.0% to +9.0%: 3 days+9.0% to +10.0%: 8 days-10%-8%-6%-4%-2%+0%+2%+4%+6%+8%+10%Dashed lines: a normal day, ±3.8%Last session +2.20%

Best day 4 Aug 2026 (+20.00%), worst 15 Sep 2026 (-8.26%).

Morepen Laboratories vs NIFTY 50, one year

Both start at 100. The shaded gap is how far Morepen Laboratories is ahead of or behind the market.

100Dec 25Mar 26Jun 26Sep 26Morepen Labora +104.5%NIFTY 50 -2.8%

Morepen Laboratories fundamentals

Quarterly results and shareholding from NSE filings. Profit is the share owed to the company’s own shareholders. Compare in the stock screener →

Market cap₹5,061 Crshares × last price
P/E (TTM)26.9on ₹3.43 EPS, last 4 quarters
Revenue₹746 CrQ2 FY27 · +81.37% YoY
Net profit₹89 CrQ2 FY27 · +117.49% YoY

Revenue

₹ crore per quarter (consolidated); L = lakh crore, k = thousand crore.

Q4 FY25: ₹466 Cr466Q4 FY25Q1 FY26: ₹425 Cr425Q1 FY26Q2 FY26: ₹412 Cr412Q2 FY26Q3 FY26: ₹484 Cr484Q3 FY26Q4 FY26: ₹485 Cr485Q4 FY26Q1 FY27: ₹570 Cr570Q1 FY27Q2 FY27: ₹746 Cr746Q2 FY27

Net profit

₹ crore per quarter (consolidated); L = lakh crore, k = thousand crore.

Q4 FY25: ₹20 Cr20Q4 FY25Q1 FY26: ₹11 Cr11Q1 FY26Q2 FY26: ₹41 Cr41Q2 FY26Q3 FY26: ₹28 Cr28Q3 FY26Q4 FY26: ₹16 Cr16Q4 FY26Q1 FY27: ₹56 Cr56Q1 FY27Q2 FY27: ₹89 Cr89Q2 FY27

Who owns Morepen Laboratories

Shareholding pattern for the quarter to 30 Sep 2026, from the company’s filing with NSE.

Promoters 35.6%Foreign investors (FII/FPI) 3.4%Insurance companies 0.8%Other domestic institutions 0.9%Retail investors 46.7%Others 12.5%

Change since Jun 2026:

Foreign investors+1.97 ptsInsurance companies-0.13 ptsOther domestic institutions+0.56 ptsRetail investors-3.04 pts

Promoter holding over time

Promoter and promoter group stake, every quarter.

2022-032026-0938.38%35.65%

Morepen Laboratories balance sheet, returns and cash flow

From the consolidated half-year and annual results filed with NSE (latest: 30 Sep 2026), on the same basis as the quarterly figures above.

ROE14.6%profit ÷ shareholders’ equity, last 4 quarters
ROCE17.7%operating profit ÷ capital employed
Debt / equity0.22borrowings (excl. leases) ÷ equity
Book value / share₹25.21P/B 3.7
Interest cover14.7×operating profit ÷ interest
Free cash flow FY26−₹128 Cryield -2.5% of market cap
EV / EBITDA16.8×enterprise value (market cap + debt − cash) ÷ operating profit before interest, tax and depreciation, last 4 quarters
Dividend payout FY2611%share of the year’s profit paid out as dividends
Net margin trend+2.0 ptsnet margin 11.9% in Q2 FY27 vs 9.9% a year earlier
Sep 2025half yearMar 2026full yearSep 2026half year
Shareholders’ equity₹1,196 Cr₹1,246 Cr₹1,381 Cr
Borrowings (excl. leases)₹145 Cr₹195 Cr₹305 Cr
Cash, bank balances & current investments₹80.9 Cr₹91.7 Cr₹271 Cr
Operating cash flow₹15.9 Cr₹32.6 Cr₹127 Cr
Capex (PPE + intangibles)₹106 Cr₹161 Cr₹89.7 Cr

Balance sheet items are as at the date shown; cash flows cover the half year or full year to that date. ₹ crore.

Morepen Laboratories vs peers

Morepen Laboratories is number 78 of 121 Pharma & healthcare companies by market cap. The table shows it with the 7 companies nearest to it in size. P/E is on the last four quarters’ profit, growth compares the latest quarter with a year earlier, Q / V / M are ChartMine scores (quality, valuation, momentum, 0–100) for 17 Nov 2026. Tap a column heading to sort.

Orchid Pharma955.955,725127.33.53.076%–8%14%162965
IOLCP189.745,57027.42.911.140%117%8%103%576480
ARTEMISMED343.405,43647.45.512.313%4%10%22%554186
Morepen Laboratories92.375,06126.93.714.681%117%12%102%505360
Senores Pharmaceuticals1,0935,03135.65.015.419%31%21%37%413945
Supriya Lifescience614.804,94927.94.015.23%−42%14%−23%695812
Gujarat Themis Biosyn362.804,724–4.6–––−28%−17%–––
Aarti Drugs505.754,61620.22.714.527%83%10%12%517388
Sector median–9,49542.04.513.321%26%12%12%544764

Sector: Pharma & healthcare (126 companies). Medians are over every Pharma & healthcare company with that figure. ₹ crore; market cap at the last close.

Morepen Laboratories cash flow

Cash generated by the business, spent on investment and returned to or raised from investors, by fiscal year (consolidated figures from the annual results). Operating cash flow covered profit in 0 of the last 2 years. Free cash flow was positive in 0 of 2 years.

YearOperating cash flowInvestingFinancingCapexFree cash flowProfitCash conversionDividends paid
FY2633−12397161−1289634%11
FY2532−322300214−18211827%0

₹ crore. Free cash flow = operating cash flow − capex. Cash conversion = operating cash flow ÷ profit. Capex and dividends are cash paid out.

Operating cash flow vs profit

₹ crore by fiscal year. When the blue bar is taller than the green one, the business turned more than its reported profit into cash.

Operating cash flowProfitFY25 Operating cash flow: ₹32 Cr32FY25 Profit: ₹118 Cr118FY25FY26 Operating cash flow: ₹33 Cr33FY26 Profit: ₹96 Cr96FY26

Morepen Laboratories dividend history, bonus and splits

From NSE’s corporate-action records since 2005. Prices on this page are already adjusted for splits and bonuses.

Morepen Laboratories dividend history

Total declared per share in each year, as announced (not adjusted for later splits or bonuses). Last 12 months: ₹0.2 a share, a 0.22% yield at today’s price.

YearDividend per sharePayouts
2026₹0.21
2025₹0.21

Latest: Dividend ₹0.2 (ex 18 Sep 2026); Dividend ₹0.2 (ex 29 Aug 2025).

Delivery and big-buyer days

Delivered shares change owners for real; intraday trades don’t. Days when delivery jumps far above normal often mean large investors were buying or selling.

Delivery, last session0%0 shares
Average, 60 sessions17%1-year median 34%
Big-buyer days, 1 year5delivery 3× normal or more

Delivery calendar, last 12 months

Each square is a session. The brighter the green, the more shares were delivered compared with Morepen Laboratories’s normal. Hover or tap a square for the day.

MWFDecJanFebMarAprMayJunJulAugSepOctNov
Hover a square
QuietBelow normalNormalHighBig-buyer day

Latest big-buyer days

What the price did on the day and five sessions later. Past moves only.

DateDeliveredvs normalDelivery %Day5 days later
28 Aug 20261.19 Cr3.2×30%+9.81%+7.11%
20 Aug 20261.19 Cr3.8×25%+9.10%+0.24%
17 Aug 20261.20 Cr3.9×26%+6.69%+6.01%
4 Aug 20261.99 Cr7.5×30%+20.00%+11.14%
12 Jun 202652.73 L4.3×29%+5.98%-1.24%
10 Sep 202541.74 L4.7×33%+4.78%+0.17%
9 Sep 202528.09 L3.2×29%+4.34%+4.12%
11 Aug 202535.66 L3.9×46%-0.51%+4.22%

Morepen Laboratories timeline

Everything that happened to Morepen Laboratories, newest first: deals, promoter filings, results, big-buyer days, new highs and big moves.

  • November 2026
  • 4 Nov
    Bulk deal: Neo Apex Share Broking Services Llp bought 36.68 L sharesAt ₹97.20, worth ₹35.6 Cr.
  • 4 Nov
    Bulk deal: Neo Apex Share Broking Services Llp sold 3,200 sharesAt ₹106.99, worth ₹0.0 Cr.
  • September 2026
  • 18 Sep
    Dividend - Re 0.20 Per ShareEx-date: buy before this day to be entitled. From NSE’s corporate actions.
  • August 2026
  • 28 Aug
    Big-buyer day: 1.19 Cr shares delivered, 3.2× normal30% of the day’s volume was delivered; the price closed +9.81%.
  • 20 Aug
    Big-buyer day: 1.19 Cr shares delivered, 3.8× normal25% of the day’s volume was delivered; the price closed +9.10%.
  • 17 Aug
    Big-buyer day: 1.20 Cr shares delivered, 3.9× normal26% of the day’s volume was delivered; the price closed +6.69%.
  • 4 Aug
    Big-buyer day: 1.99 Cr shares delivered, 7.5× normal30% of the day’s volume was delivered; the price closed +20.00%.
  • 4 Aug
    New 52-week high at ₹69.18First new high in over 20 sessions.
  • 4 Aug
    Jumped 20.0% in one sessionClosed at ₹69.18, about 5.2× a normal day’s move.
  • June 2026
  • 12 Jun
    Big-buyer day: 52.73 L shares delivered, 4.3× normal29% of the day’s volume was delivered; the price closed +5.98%.
  • 9 Jun
    Jumped 13.5% in one sessionClosed at ₹48.65, about 3.5× a normal day’s move.
  • February 2026
  • 23 Feb
    Jumped 15.4% in one sessionClosed at ₹45.28, about 4.0× a normal day’s move.
  • September 2025
  • 10 Sep
    Big-buyer day: 41.74 L shares delivered, 4.7× normal33% of the day’s volume was delivered; the price closed +4.78%.
  • 9 Sep
    Big-buyer day: 28.09 L shares delivered, 3.2× normal29% of the day’s volume was delivered; the price closed +4.34%.
  • August 2025
  • 29 Aug
    Dividend - Re 0.20 Per ShareEx-date: buy before this day to be entitled. From NSE’s corporate actions.
  • 11 Aug
    Big-buyer day: 35.66 L shares delivered, 3.9× normal46% of the day’s volume was delivered; the price closed -0.51%.
  • 8 Aug
    Big-buyer day: 39.60 L shares delivered, 4.3× normal49% of the day’s volume was delivered; the price closed -5.32%.
  • 7 Aug
    Big-buyer day: 47.62 L shares delivered, 5.2× normal42% of the day’s volume was delivered; the price closed -6.71%.

My notes on Morepen Laboratories

Private: saved only in this browser, never sent to us.

Questions

What is the 52-week high and low of Morepen Laboratories?
Over the last 52 weeks, Morepen Laboratories (MOREPENLAB) traded between ₹33.05 and ₹150.70 (adjusted for splits and bonuses). The last close of ₹92.37 on 18 Nov 2026 is 38.7% below the high.
What is the delivery percentage of Morepen Laboratories?
On 18 Nov 2026, 0.0% of Morepen Laboratories’s traded shares were delivered. The 60-session average is 16.5%, and its median over the last year is 34.1%.
How volatile is Morepen Laboratories?
Morepen Laboratories’s daily moves over the last year add up to 61% annual volatility, higher than 97% of the 1,443 most traded NSE stocks. Its average day spans 6.3% from high to low.
What is the market cap of Morepen Laboratories?
About ₹5,061 Cr, from 547,900,000 shares at the last close.
What is the P/E ratio of Morepen Laboratories?
26.9, the last close divided by earnings per share of ₹3.43 over the last four reported quarters.
Who owns Morepen Laboratories? What is its shareholding pattern?
As of 30 Sep 2026: promoters 35.65%, foreign investors 3.43%, mutual funds 0.00%, insurance companies 0.81% and retail investors 46.71%.
How were Morepen Laboratories's latest quarterly results?
In Q2 FY27 (quarter to 30 Sep 2026), revenue was ₹746 Cr (+81.37% year on year) and net profit ₹89 Cr (+117.49%).
What is the ROE of Morepen Laboratories?
Morepen Laboratories’s return on equity was 14.6% over the last four quarters: profit attributable to shareholders divided by average shareholders’ equity (consolidated figures, balance sheet as at 30 Sep 2026).
Is Morepen Laboratories debt free?
No. Borrowings (excluding lease liabilities) were 0.22× equity as at 30 Sep 2026.
What is the book value of Morepen Laboratories?
₹25.21 per share (consolidated shareholders’ equity as at 30 Sep 2026 divided by shares outstanding), a price-to-book of 3.7.
Who are Morepen Laboratories’s peers?
Among Pharma & healthcare companies listed on NSE, the ones closest to Morepen Laboratories by market cap are Orchid Pharma, IOLCP, ARTEMISMED, Senores Pharmaceuticals, Supriya Lifescience, Gujarat Themis Biosyn and Aarti Drugs. Pharma & healthcare has 126 companies in ChartMine’s data. Morepen Laboratories has a P/E of 26.9 against the sector median of 42.0 and a return on equity of 14.6% against 13.3%.
Does Morepen Laboratories generate cash?
In FY26, Morepen Laboratories’s operating cash flow was ₹33 crore against profit of ₹96 crore (34% cash conversion); capex of ₹161 crore took free cash flow to −₹128 crore. Operating cash flow covered profit in 0 of the last 2 years, and free cash flow was positive in 0 of 2.
Has Morepen Laboratories given bonus shares or split its stock?
NSE’s corporate-action records since 2005 show no bonus issue or stock split for Morepen Laboratories.
Does Morepen Laboratories pay dividends?
Yes. Morepen Laboratories’s most recent dividend was ₹0.2 a share (dividend, ex-date 18 Sep 2026). Over the last 12 months it declared ₹0.2 a share, a 0.22% yield at the latest price.
What are the support and resistance levels of Morepen Laboratories?
Over the last year, the most Morepen Laboratories shares were delivered around ₹78.50 below the current price and ₹119 above it (last close ₹92.37 on 18 Nov 2026). These busy zones often act as support and resistance, but they describe the past, not the future.
What is the ISIN of Morepen Laboratories?
Morepen Laboratories’s ISIN is INE083A01026. It trades on NSE as MOREPENLAB and on BSE under code 500288, with a face value of ₹2 per share, and has been listed on NSE since 24 November 1999.

Data from NSE’s daily files, adjusted for splits and bonuses. Past behaviour is not a forecast. This is information, not investment advice; ChartMine is not a SEBI-registered adviser.

See it live on your chart.ChartMine for TradingView.